<DOC>
	<DOC>NCT01615250</DOC>
	<brief_summary>This is a randomized study of efficiency and safety of intramyocardial implantation of peripheral mononuclear cells with high concentration of CD34+ stem cells in patients with myocardial ischemia after preparatory course of shock - wave therapy.</brief_summary>
	<brief_title>Implantation of Peripheral Stem Cells in Patient With Ischemic Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Patients with ischemic cardiomyopaty and HF IIIV NYHA class MI more than 6 months before the study LVEF less than 35% Absence effect of coronary revascularization during 6 months Optimal pharmacological therapy no less than 8 weeks Heart transplantation is contraindicated Patients with implantable cardioverterdefibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRTD) Patients giving informed consent Acute coronary syndrome Coronary revascularization less than 6 months Patients requiring surgical correction of postMI aneurism LV wall thickness less than 5 mm in site of possible injection Patients with CRT implanted within 3 month before cells injection Clinically significant associated diseases Active oncology desiase Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>